agree, as per the PK headline:
- effective target cells engaged (intracellular miracle in itself)
- long cellular engagement duration (relatively)
- safe (min off targets reported)
PYC pipeline image has been refreshed on their website to list OPA1 as a co-lead, anticipate refining of the shared delivery backbone to show even greater effectiveness/efficiency data.
Rinse and repeat hopefully for Glaucoma and other IRD.
And then there’s CNS/Kidney to come.
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-28
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.5¢ | $142.7K | 751.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 204334 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 345272 | 11 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |